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Background: Comprehensive evidence on the incidence, time course and independent risk factors of metachronous
peritoneal carcinomatosis (metaPC) in gastric cancer patients treated with curative intent in the context of
available systemic combination chemotherapies is lacking.
Methods: Data from a prospectively collected single-institutional Center Cancer Registry with 1108 consecutive
patients with gastric adenocarcinoma (GC), clinical, histological and survival data were analyzed for independent
risk factors and prognosis with focus on the development of metaPC. Findings were then stratified to the time
periods of treatment with surgery alone, 5-Fluorouracil-only and contemporary combined systemic perioperative
chemotherapy strategies, respectively.
Results: Despite R0 D2 gastrectomy (n = 560), 49.6% (±5.4%) of the patients were diagnosed with tumour
recurrence and 15.5% (±1.8%) developed metaPC after a median time of 17.7 (15.1-20.3) months after surgery
resulting in a tumour related mortality of 100% with a median survival of 3.0 months (2.1 – 4.0). Independent risk
factors for the development of metaPC were serosa positive T-category, nodal positive-status, signet cell and
undifferentiated gradings (G3/G4). Contemporary systemic combination chemotherapy did not improve the
incidence and prognosis of metaPC (p = 0.54).
Conclusions: Despite significant improvements in the overall survival for the complete cohort with gastric cancer
over time, those patients with metaPC did not experience the same benefits. The lack of change in the incidence,
and persistent poor prognosis of metaPC after curative surgery expose the need for further prevention and/or
improved treatment options for this devastating condition.
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Although the incidence and cancer-related mortality of
gastric carcinoma (GC) have been decreasing steadily
during the past century, it remains one of the most com-
mon malignancies and the second leading cause of can-
cer death worldwide [1-3]. Up to 60% of GC patients are
at an advanced stage at initial diagnosis [4], with a 5-
year survival rate of approximately 25% [5]. These older
institution-based data have been confirmed by a recent
European population-based study with 39% of patients
having metastatic disease and 14% syncronous peritoneal
carcinomatosis (synPC) at primary diagnosis respectively
[4]. Patients with locally advanced lesions experience a
high recurrence rate even after R0 resection by gastrec-
tomy with standard D2 lymphadenectomy has been
achieved [5]. Thus, different perioperative multimodal
treatment regimens have been introduced during the
last two decades. These vary from adjuvant chemo-
radiotherapy currently preferred in the U.S. and Canada
[6], a pre- or post-operative chemotherapy in Europe,
postoperative chemotherapy [7,8] for 1 year in Japan, to
postoperative chemotherapy with capecitabine and oxali-
platin for 6 months in Korea [8,9]. Perioperative chemo-
therapy has been shown to downsize and downstage
gastric cancer in up to 43% of patients [10], up to the
point of complete pathological response [11-13].
These developments have enabled physicians to offer
patients even with locally advanced or metastatic stage
at diagnosis, − a curative therapy [11-13]. Despite them,
the proportion of metachronous tumour progression re-
mains high and data on surgical and survival benefits of
the perioperative chemotherapy have been controversial
[10]. It has been argued that a perioperative chemother-
apy induced downsizing and downstaging of the tumour
may enable curative surgery with, however, initial bene-
fits diminishing in the long term [10].
Although initially encouraging results from cytoreduc-
tive surgery and intraperitoneal chemotherapy in highly
selected patients were reported, patients diagnosed with
metachronous peritoneal carcinomatosis (metaPC) still
face a poor prognosis [14-16]. Therefore, strategies aim-
ing to prevent or at least delay metachronous dissemin-
ation seem to be a sound therapeutic approach in
patients at high risk of recurrence [17,18].
As there has been no evidence for surveillance related
survival benefit [19,20], neither the German S3 guidelines
nor the ESMO-ESSO-ESTRO Clinical Practice Guidelines
recommend standardized follow up. The vast majority of
the data leading to this recommendation did, however, not
emphasise both the current perioperative combination
chemotherapeutic regimes available [21,22] and the avail-
ability of new promising treatment options [16-18].
Clarifying the relationship between clinicopathological
factors, different perioperative treatment regimens andindependent risk factors of recurrence can add valuable
information and may lead to improved treatment and
follow up programs in patients at high risk of recur-
rence. Here we report long-term results from the largest
cohort of gastric cancer patients to our knowledge and
focus on the incidence and time course of tumour pro-
gression in patients treated with curative intent, and




For this study, all consecutive patients with GC treated
at the University of Wuerzburg Medical Center Cancer
Registry (UWCR) between January 1986 and July 2013
were identified from the Cancer Registry of Wuerzburg
University Medical Center. Patients diagnosed with
other than adenocarcinoma of gastric origin or having
any other carcinoma or without complete follow up were
excluded. Patients were grouped into three equally long
time periods ranging from 1986 to 1994 (time period I),
1995 to 2004 (time period II) and from 2005 to July
2013 (time period III) each covering profound changes
in perioperative therapy, staging standards and/or diag-
nostic imaging available (Table 1).
Patients with synPC were diagnosed at the time
of presentation with GC, either on routine staging,
computed tomography or at laparotomy. Patients with
metaPC were considered to be clear of peritoneal dis-
ease at the initial curative intended surgery with R0
resection, but subsequently became symptomatic on
follow-up and were diagnosed with peritoneal metasta-
ses on computed tomography or at the time of another
surgical exploration.
Data source and follow up
UWCR is a central data repository maintained by the
tumour registry institute of the University of Wuerzburg.
It has expanded prospectively since 1985 with clinical,
operative and research data of patients who were evalu-
ated and treated at the University of Wuerzburg Medical
Center. From 1985 to May 2014 it includes 146,522 pa-
tient records. Data available within the UWCR include
patient demographics, histological diagnoses that are
based on International Classification of Diseases coding
standards (UICC Version VII, [23]), general practitioner
records, inpatient admission and outpatient registration
data, operating room procedures, laboratory results and
computerized pharmacy records. The UWCR undergoes
continuous cross platform integration with the Compre-
hensive Cancer Registry to ensure updated follow-up
information for identification of deceased patients. In-
patient and outpatient records of all identified patients
were reviewed retrospectively to extract information
Table 1 Demographic and pathological tumour characteristics of 1072 patients without 30-day mortality constituting
the basis for survival calculations
Demographics and pathological tumor characteristics (n = 1108)
Epidemiology
Patients Time period I Time period II Time period III p-value All time periods
(1986–1994) (1995–2003) (2004 – 2013)
n = 363 (32.8%) n = 349 (31.5%) n = 396 (35.7%) n = 1108 (100%)
30d mortality 8 14 14 0.37 36
(2.2%) (4.0%) (3.5%) (3.2%)
Patients w/o 30d-mortality n = 355 n = 335 n = 382 n = 1072
(33.1%) (31.2%) (35.6%) (100%)
Median age (y) 63.81 65.56 65.70 y 0.13* 65.05 y
(19.59 -91.24) (34.33 -91.58) (21.78 - 93.91) (19.59 - 93.91)
Gender m/f 224/131 (63.1/36.9%) 216/119 (64.5/35.5%) 243/139 (63.6/36.4%) 0.93 683/389 (63.7/36.3%)
Tumor characteristics/staging of patients w/o 30d mortality (n = 1072)
UICC stage I 82 (23.1%) 82 (24.5%) 103 (27.0%) 0.47 267 (24.9%)
UICC stage II 83 (23.4%) 102 (30.4%) 100 (26.2%) 0.11 285 (26.6%)
UICC stage III 63 (17.7%) 42 (12.5%) 57 (14.9%) 0.16 162 (15.1%)
UICC stage IV 111 (31.3%) 105 (31.3%) 114 (29.8%) 0.88 330 (30.8%)
UICC stage X 16 (4.5%) 4 (1.2%) 8 (2.1%) 0.02 28 (2.6%)
T1/Tis 61 (17.2%) 50 (14.9%) 61 (16.0%) 0.72 172 (16.0%)
T2 107 (30.1%) 141 (42.1%) 89 (23.3%) <0.001 337 (31.4%)
T3 89 (25.1%) 79 (23.6%) 124 (32.5%) 0.015 292 (27.2%)
T4 76 (21.4%) 58 (17.3%) 92 (24.1%) 0.084 226 (21.1%)
Tx 22 (6.2%) 7 (2.1%) 16 (4.2%) 0.027 45 (4.2%)
N0 95 (6.8%) 99 (29.6%) 137 (35.9%) 0.023 331 (30.9%)
N1 55 (15.5%) 98 (29.3%) 132 (34.6%) <0.001 285 (26.6%)
≥ N2 168 (47.3%) 119 (35.5%) 82 (21.5%) <0.001 369 (34.4%)
Nx 37 (10.4%) 19 (5.7%) 31 (8.1%) 0.074 87 (8.1%)
G1 11 (3.1%) 5 (1.5%) 7 (1.8%) 0.302 23 (2.1%)
G2 79 (22.3%) 99 (29.6%) 99 (25.9%) 0.091 277 (25.8%)
G3 142 (40.0%) 209 (62.4%) 239 (62.6%) <0.001 590 (55.0%)
G4 7 (2.0%) 1 (0.3%) 8 (2.1%) 0.093 16 (1.5%)
Gx 116 (32.7%) 21 (6.3%) 29 (7.6%) <0.001 166 (15.5%)
Signet Ring Cell 13 8 7 0.284 28
3,7% 2,4% 1,8% 2,6%
synPC 35 (9.9%) 49 (14.6%) 74 (19.4%) 0.001 158 (14.7%)
synPC (isol.) 11 (3.1%) 30 (9.0%) 45 (11.8%) <0.001 86 (7.9%)
synM+(*) 99 (27.9%) 75 (22.4%) 68 (17.8%) 0.005 242 (22.6%)
synFM (isol.) 75 (21.1%) 56 (16.7%) 39 (10.2%) <0.001 170 (15.9%)
synPC/synM+(*) 24 (6.8%) 19 (5.7%) 29 (7.6%) 0.591 72 (6.7%)
The characteristics are stratified for the three time period of treatment (*Kruskal-Wallis-Test)
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metastatic disease at presentation and disease status at
last follow-up.
Patients received a symptom based follow-up accord-
ing to the German S3 and the ESMO-ESSO-ESTROClinical Practice Guidelines [8,19]. Follow up data were
obtained following contact with the family doctors on
a regular basis (minimum 6 months), active collection
of oncological outpatient consultation letters and path-
ology laboratory reports as well as automatic retrieval of
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(minimum once a year). The ‘Death Certificate Only’
(DCO) rate in this database is 0.2 and the completeness
of follow up index is better than 0.9. For the patients in
this study the follow up rate is 100%. Autopsy was not
performed routinely. Demographic details of the three
groups were compiled, along with clinical variables re-
corded at the time of primary diagnosis as well as at ini-
tial operation (tumour site and the presence of any
metastases) and histological details of the resected speci-
men (tumour (T) category, nodal (N) category, tumour
differentiation (G) and evidence of microscopic venous
(V) and lymphatic vessel invasion (L)).
Metastases diagnosed within 30 days after the primary
tumour were also defined as synchronous [23]. Periton-
eal carcinomatosis was diagnosed usually intraopera-
tively and confirmed histopathologically and in other
cases by computed tomography.
This study has been approved for full ethics waiver
due to its retrospective nature by the University of
Wurzburg ethics committee.
Statistical analysis
The data were analyzed with SPSS, Statistical Package
for Social Sciences, version 16, SPSS, Chicago, IL, USA.
Clinical and histological parameters of the three groups
were compared with the Mann–Whitney U or Kruskal–
Wallis test for continuous data and with the w2 test for
categorical variables. P < 0.05 was considered statistically
significant. Univariate survival analysis was performed
with the Kaplan Meier method. Cox proportional hazard
modeling or “Cox regression” was used to determine
predictors for the development of metaPC by analyzing
the group patients that were tumour free after initial
oncological therapy whenever univariate analysis showed
any significance.
Results
From January 1986 to July 2013 a total number of 1,372
consecutive patients with gastric cancer were identified
from the Wuerzburg Medical Centre Cancer Registry
(UWCR). Out of those, 1,108 patients were diagnosed
with adenocarcinoma of gastric origin, without having
any other carcinoma and with complete follow up. Pa-
tients without 30d-Mortality (n = 1072) were grouped
into three equally long time periods ranging from 1986
to 1994 (time period I, n = 382), 1995 to 2004 (time
period II, n = 335) and from 2005 to July 2013 (time
period III, n = 355) each covering profound changes in
perioperative therapy and staging standards as stated
above.
Demographics and pathological tumour characteristics
are presented in Table 1. Mean age of the entire cohort
was 65.1 (Range 19.6-93.9) years with 36% female and64% male patients. There were no significant differences
in demographic characteristics such as age (p = 0.13),
gender (p = 0.93), and clinical characteristics (UICC7
Stage I-IV) at the time of surgery among the patients of
the three different time periods. A consistent staging of
patients during time period I was not available in 4.5%
of patients which was more frequent condition com-
pared to time periods II and III (p = 0.02). Patients of
time period III were more often diagnosed with locally
advanced tumours (T3/T4, p < 0.001) but less frequently
diagnosed with positive nodal status (p = 0.014) com-
pared to patients of time period I and II. There were no
significant differences among the particular tumour
grading during time periods II and III. Of note, an ac-
curate tumour grading was not applicable in 32.7% of
the patients of time period I (p < 0.001).
Both a synPC and an isolated synPC were more fre-
quently diagnosed in patients of time period III vs. time
period I and II (p < 0.001). In contrast, a synPC meta-
static state in sites other than the peritoneum, was more
often diagnosed in patients of time period I and II (p =
0.005).
Overall, 95.1% of the patients received any treatment
(surgery, chemotherapy), with 90.0% of the patients
undergoing any type of surgery during their course of
disease (palliative procedures included). Gastrectomy
with D2 lymphadenectomy was performed in 60.7%
(n = 605) of the patients with a significantly higher pro-
portion in time period III compared to time period I
(p = 0.001). Thereof, R0 resection was achieved in 92.6%
(n = 560) overall. These parameters did not significantly
differ among the patient cohorts of different time periods
(Table 2). After curative resection 30- and 90-day mor-
tality were 2.0% and 5.5% respectively with no signifi-
cant differences among the different time periods (p =
0.34 and 0.46).
Perioperative chemotherapy was applied to 12.4%
(time period I) vs. 17.2% (time period II) vs. 53.2 (time
period III, p < 0.001) of the patients with perioperative
combination chemotherapeutic regimes being given more
often in time period III compared to time period I and
II (p < 0.001).
Detailed follow-up and survival data are presented in
Table 3. Duration of overall follow up was 36.9 months
(range 0–258). Median overall survival was 25.2%
(±2.2%) with a longer median survival in patients of time
period III compared to patients of time periods I and II
(p = 0.37). Accordingly, the 2-, 5-, and 10-year survival
rate were significantly higher in time period III com-
pared to time periods I and II (p < 0.001).
Mean duration of follow up after R0 resection was 58.8
(+/−) months. The 2-, 5-, and 10-year survival rate were
83.2%, 65.7% and 59.0% respectively. There were no sig-
nificant differences among the different time periods.
Table 2 Overview of the therapy all patients received during the three treatment time periods
Therapy (all patients n = 1108)
Time period I Time period II Time period III p-value* All time periods
(1986–1994) (1995–2003) (2004 – 2013)
Any therapy 341 (93.9%) 331 (94.8%) 382 (96.5%) 0.260 1054 (95.1%)
Any operation 332 (91.5%) 318 (91.1%) 347 (87.6%) 0.148 996 (90.0%)
D2 gastrectomy 178 (53.3%) 196 (61.6%) 231 (66.8%) 0.001 605 (60.7%)
30d mortality 3 (1.7%) 2 (1,0%) 7 (3.0%) 0.314 12 (2.0%)
90d mortality 8 (4.5%) 9 (4.6%) 16 (6.9%) 0.456 33 (5.5%)
tumor-free 157 (88.2%) 184 (93.9%) 219 (94.8%) 0.085 560 (92.6%)
Thereof w/o 30d-mortality 155 (98.7%) 182 (98.9%) 213 (97.3%) 0.390 550 (98.2%)
Chemotherapy 45 (12.4%) 60 (17.2%) 211 (53.3%) <0.001 316 (28.5%)
5-FU 40 (11.0%) 45 (12.9%) 3 (0.8%) <0.001 88 (7.9%)
Combination* 5 (1.4%) 4 (1.1%) 101 (25.5%) <0.001 110 (9.9%)
Combination + antibody** 0 (0%) 0 (0%) 16 (4%) <0.001 16 (1.4%)
Chemoregimen undocumented 0 (0%) 11 (3.2%) 91 (8.2%) <0.001 102 (9.2%)
Perioperative chemotherapy in curative treated and RO patients (N = 550)
Patients 155 182 213 550
Perioperative therapy 0 (0%) 0 (0%) 64 (30.0%) <0.001 65 (11.6%)
No perioperative therapy 155 (100%) 182 (100%) 148 (70.0%) <0.001 485 (88.4%)
Chemotherapy includes perioperative as well as second-line and palliative therapy. Information on neoadjuvant chemotherapy is provided on 550 patients after
R0 gastrectomy and D2 lymphadenectomy.
*Combination of 5-FU and/or oxaliplatin, irinotecane, cisplatin, epirubicin, doxorubicin, cyclophosphamide **combination as described above + antibody therapies
(Trastuzumab, Panitumumab, Catumaxumab).
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more frequently with metachronous metastatic state if
compared to patients of time period III (p = 0.01), while
patients of time period III were more often diagnosed with
isolated metaPC (p = 0.03).
Pathological tumour characteristics of patients who re-
ceived perioperative chemotherapy were not different to
those of patients who did not (p = 0.47). Neoadjuvant
chemotherapy neither impacted on survival nor on the
time course of tumour recurrence (Table 4).
Overall survival was improved in patients (n = 1072)
treated in time period III (26,0 months (range 20,5 -
31,5)) compared to patients of time period I (16,0 months
(range 12,5 to 19,4; p = 0.07) and compared to time
period II (18.0 months (range 14,0 to 22,0; p = 0.031,
Figure 1).
After R0 D2 gastrectomy (n = 550) we did not observe
significant survival differences among patients treated in
different time periods (time period I: 68,0 months (range
45,8 to 90,2) vs. time period II: 60,2 months (range 46,3
to 74,1) vs. time period III (65,0 months (range 39,4 to
90,6; p = 0.67).
The cumulative Hazard risk for metaPC was increased
for patients treated in time period III compared to those
being treated in time periods II and III (p = 0.023,
Figure 2a). Survival of patients diagnosed with synPC
was in trend prolonged in time period III compared totime period I (p = 0.58, Figure 2b). There was no era
specific survival difference in patients diagnosed with
metaPC (p = 0.34, Figure 2c). The histopathological
characteristics such as undifferent ‘gradings’ (G3/4, fac-
tor: 2.03 (3.65-1.13, p = 0.018), nodal positive category
(N+, factor: 2,39 (4,26-1,34, p = 0.003), signet ring cell
(factor: 3,88 (9,71-1,56, p = 0.004), and locally advanced
tumour category (T3/4, factor: 2.35 (1.35-4.12, p =
0.003) were identified to be independent risk factors for
the development of metaPC after R0 D2 gastrectomy
(n = 550). Other factors, such as time period of treat-
ment, age, gender, and perioperative therapy did not
impact on the risk of metaPC in multivariate analysis
(Table 5, Figure 2b).
Discussion
Data from our cohort, which is to our knowledge the
largest ever studied, show that neither the incidence nor
the time course and prognosis of metachronous periton-
eal carcinomatosis in gastric cancer patients treated with
curative intent, have changed over the last three decades.
Our data are in line with previous studies reporting an
advanced tumour stage in 45.9 percent of the patient co-
hort and with synPC PC in 14.6 percent at primary diag-
nosis respectively [4]. Our findings show that tumour
stage at diagnosis has not changed and, especially, the
rates of synPC has not decreased within the last two
Table 3 Tumour related overall survival of the entire patient cohort without 30-day-mortality (n = 1072) and of
patients that were R0 after gastrectomy and D2-lymphadenectomy, stratified for the three time periods of treatment
Follow up of patients w/o 30d-mortality of operated patients (n = 1072)
Time period I Time period II Time period III p-value*
(1986–1994) (1995–2003) (2004 – 2013)
Mean follow up time (months) 45,3 41,5 25,0 <0.001 36.9
(0 – 257.97) (0–212.99) (0–111.97) (0 – 257.97)
Median overall survival [months] 21.9 (±4.36) 21.0 (±2.27) 32.4 (±5.75) 0.037 25.2 (±2.20)
2y-survival rate [SE], n (Patients at risk) 49.7% 47.2% 57.3% <0.007 51.4%
(±2.8) n = 148 (±2.8),n = 143 (±2.9) n = 148 (±1.6) n = 439
5y-survival rate [SE], n (Patients at risk) 36.5% 35.1% 41.6% (±3.2) <0.043 37.8% (±1.7)
(±2.8) n = 88 (±2.7) n = 95 n = 46 n = 229
10y-survival rate [SE], n (Patients at risk) 33.8% (±2.8) n = 68 29.7% (±2.7) n = 45 38.5% (±3.4) n = 50 < 0.037 33.4% (±1.7), n = 113
Follow up after RO resection (w/o 30d mortality, n = 550)
Mean follow up time [months] 83.1 (1.02 – 257.97) 66.4 (1.02 – 212.99) 34.7 (1.0 - 111.97) 58.8 (1.02 – 257.97)
Median overall survival (months) Not reached Not reached Not reached Not reached
75% survival [months] 47.0 (±5.7) 28.0 (±5.7) 33.0 (±7.0) 0.313 34.3 (±4.1)
2y-survival rate [SE], n (Patients at risk) 86.9% (±2.8) 79.5% (±3.1) 83.6% (±2.9) 0.188 83.2% (±1.7)
n = 119 n = 129 n = 124 n = 372
5y-survival rate (SE), n (Patients at risk) 68.7% (±4.0) 61.9% (±3.9) 68.7% (±4.0) 0.340 65.7% (±2.3)
n = 78 n = 90 n = 42 n = 210
10y-survival rate (SE), n (Patients at risk) 61.9% (±4.4) 54.3% (±4.1) – 0.270 59.0% (±2.6)
n = 60 n = 44 n = 104
metaPC (general) 10.5% (±2.8) 16.1% (±3.1) 18.9% (±3.3) 0.074 15.5% (±1.8)
n = 13 n = 23 n = 28 n = 64
Recurrence 49.5% (±6.7) 46.4% (±4.0) 38.2% (±4.4) 0.523 49.6% (±5.4)
n = 59 n = 74 n = 55 n = 188
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cent European population based study [4]. This could
firstly be explained by the fact that screening for gastric
cancer is only recommended for a small proportion of
people with well-established risk factors [19,24,25], and
secondly, by the overall poor perception of any cancer
screening programs [26].
As conclusions on synPC in gastric cancer in a single-
centre study need to be drawn with caution we moved
on and focused on the incidence of metaPC in our co-
hort of 1,108 patients with a median follow up of
36.9 months and a follow up rate of 100 percent.
For further analysis we excluded patients with both,
a metastatic state and/or positive margins after D2
gastrectomy, as they are associated with a very poor
prognosis, [27,28] and revisional surgery and/or radio
chemotherapy is recommended under these circum-
stances [19,20]. Despite Ro D2 gastrectomy 50% of the
patients were diagnosed with tumour recurrence, 16%
developed metaPC after a median time of 17.7 (15.1-
20.3) months from surgery resulting in a tumour
related mortality of 100% with a median survival of3 months. The data on the incidence of metaPC from
this study, however, vary considerably [29-33] with that
previously reported, as in our cohort peritoneal tumour
progression occurred in up to 60% of patients. The
differences in the results of our study cohort could be
explained by several reasons. Firstly, baseline demo-
graphic and tumour characteristics of our patient co-
hort were different to those of other studies. Secondly,
the vast majority of the previous findings were obtained
from an Asian population being reported to develop
gastric cancer with a more malignant tumour biology
[33]. Thirdly, the patient cohorts of those studies may
have had a more structured follow up postoperatively,
more extensively exploiting the prevalence reserve of
metachronous PC. Fourthly, older studies were pub-
lished more than 13 years ago and therefore did not
incorporate the currently available perioperative che-
motherapeutic regimes [5,10]. For this precise reason
we performed a subgroup analysis using three time
periods based on the different perioperative chemother-
apeutic regimes available over the last few decades
(Table 2).
Figure 1 Survival. a) Overall survival among the different time periods of
resection/vs. residual tumour. c-e) Survival among the different time period
Table 4 Overview of stage, overall survival and tumour-
free survival of 550 tumour-free patients after initial
therapy stratified for neoadjuvant systemic therapy






n = 64 n = 486
pUICC7 I 24 224 0.47
(37.5%) (46.1%)
pUICC7 II 28 197
(43.8%) (40.5%)
pUICC7 III 11 56
(17.2%) (11.5%)




Not reached Not reached 0.41
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(Standard error)
28.9% (±6.1) 36%.9 (±4.4)
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proved overall survival in patients treated with modern
combination chemotherapies during time period III
[5,34]. Survival after R0 D2 gastrectomy did, however,
not differ in patient among the different time periods. It
appears that patients diagnosed with metaPC also did
not experience survival benefits as the subgroup analysis
did not show significant survival differences among the
three different time periods. Interestingly, patients in
our cohort were more often diagnosed with metaPC and
had an increased risk for metaPC during the most recent
time period compared to the patients treated within the
earlier time periods. However, multivariate analysis did
not show that the time period of treatment itself was an
independent risk factor for the incidence and prognosis
of metaPC (Table 5, Figure 3).
The higher incidence of metaPC during the most re-
cent time period may, on one hand, reflect the usage of
an improved and, therefore, more sensitive imaging
technology [35]. We also assumed that patients under-
went imaging studies more frequently as potent second
and third line chemotherapeutic regimes became avail-
able and were applied more frequently to these patients.
Although pathological staging characteristics (measuredpatients without 30-day mortality (n = 1072). b) Overall survival after R0
s based on UICC staging system.
Figure 2 Peritoneal carcinomatosis. a) Cumulative hazard ratio for the development of metaPC (550 after R0 resection, stratified for the three
time periods.) b) Tumour related overall survival of 167 patients with synchronous peritoneal carcinomatosis (synPC) stratified for time periods I
and III. c) Tumour related overall survival from the time of diagnosis metachronous peritoneal carcinomatosis (metaPC) in the group of 550 patients
that were R0 after initial therapy.
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at the time point of surgery, a locally advanced tumour
was found more frequently in patients in time period III.
Multivariate analysis revealed that a serosa positive
tumour category was an independent risk factor for the
development of metaPC (Table 5, Figure 3), which is in
line to previous reports [36,37]. Further, it is probable
that the use of perioperative chemotherapeutic regimenTable 5 Analysis using Cox regression model for independen
Risk factors for metachronous peritoneal carcinomatosis
Risk factor








*Is the factor by witch the risk for development of metachronous PC is increased.during the last decade may have downsized and down-
staged the tumour enabling curative surgery with benefits
diminishing in the long term [10]. Therefore, it could be
argued that the perioperative therapy may have enabled a
curative treatment in a substantial number of patients
who most likely would have been treated using pallia-
tive intentions in the former time periods. It has firstly
been hypothesized that preoperative chemotherapy mayt risk factors after R0 D2 gastrectomy (n = 550)
P Factor* (CI 95% confidence interval)
0,003 2,35 (1,35 - 4,12)
0,004 3,88 (1,56 - 9,71)
0,003 2,39 (1,34 - 4,26)
0,018 2,03 (1,13 - 3,65)
0,247 1,39 (0,69 - 2,81)
0,776 0,82 (1,65 - 0,41)
0,399 1,25 (2,08 - 0,75)
py 0,392 0,68 (1,64 - 0,28)
Figure 3 Cox regression multivariate analysis for independent
risk factors for the development of metaPC. X-axis shows the
factor by which the risk is influenced (logarithmic diagram). P-Values
and risk factors are summarized in the table below the graph.
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therefore reduce the likelihood of malignant biological
active cell spread into the peritoneal cavity during sur-
gery [34]. In addition, tumour dissemination during
surgery through the opening of lymphatic channels
lymph node dissection and spread of viable cancer cells
into the peritoneal cavity during could be reduced [10].
However, we did not observe a clear benefit in our
cohort.
Multivariate analysis did not identify perioperative
chemotherapy, age and gender as independent risk fac-
tors for the development of metaPC (Table 5, Figure 2b).
Other histopathological characteristics such as undiffer-
entiated ‘gradings’ (G3/4), nodal positive category (N+),
signet ring cell (SRC), and serosa positve tumour cat-
egory (T3/4) were identified to be independent risk fac-
tors (Table 5, Figure 3), which is consistent to the
literature [38,39]. Notably, median survival of patients
diagnosed with metaPC was consistently shorter com-
pared to patients diagnosed with synPC with no trend in
further subgroup analysis. This may indicate that a sys-
tematic follow up of patients at high risk of tumour pro-
gression may be beneficial if strategies to treat PC
become available. Despite improvements in overall sur-
vival, the time course and occurrence rate of metaPC as
well as prognosis did not improve over time. Consider-
ing these disappointing results two conclusions need to
be drawn: Firstly, other strategies aiming to prevent or
at least relevantly delay metachronous dissemination
may be a reasonable approach. A combined strategy of
cytoreductive surgery and intraperitoneal chemotherapy
showed favorable results in highly selected patients [16].This multimodal treatment is currently regarded as the
only therapeutic option for selected patients with PC
from gastric cancer, reporting improved 5-year survival
rates ranging from 13 to 28% [14,15]. Secondly, patients
treated with curative intention (D2 gastrectomy plus
state of the art chemotherapy) at high risk for metaPC
could be tailored to other therapeutic approaches such
as the extensive intraoperative peritoneal lavage (EIPL).
This straightforward adjuvant surgical technique has
been advocated as a useful tool for those gastric cancer
patients who are likely to suffer from peritoneal recur-
rence [17,18]. In a randomized controlled study the
effect of EIPL therapy on prevention of peritoneal recur-
rence on patients with peritoneal free cancer cells with-
out overt peritoneal metastasis was verified [17,18].
Another strategy analogous to that proposed by Elias
et al. could potentially apply for patients diagnosed with
gastric cancer. Elias et a. scheduled patients diagnosed
with colorectal cancer at high risk for metaPC to a sec-
ond look laparotomy routinely even though imaging
studies did not reveal any signs of recurrence at this
time point [40].
Conclusions
Despite significant improvements in the overall survival
for the complete cohort with gastric cancer over time,
those patients with metaPC did not experience the same
benefits. Our data show that neither the incidence nor
the prognosis of metachronous peritoneal carcinoma-
tosis in gastric cancer patients treated with surgery and
modern systemic chemotherapy has changed. Therefore,
efforts should be made to accelerate the development
and implementation of improved prevention and/or
treatment options for this devastating condition. We ad-
vocate that patients at risk should be tailored to pro-
spective trials in order to increase the evidence for
promising treatment options.
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